Terumo To Start U.S. Stent Trials
This article was originally published in PharmAsia News
Major Japanese medical device maker Terumo will start clinical trials for Misago, a peripheral self-expanding stent indicated for femoral and popliteal artery disease in the U.S and Japan within the year. The company launched the product in Europe aiming for ¥10 billion in annual sales. Last year, Terumo opened a Swiss location for the launch of Nobori, a new generation of drug-eluting stent used in patients suffering from coronary artery disease, and Misago. (Click here for more - Japanese language
You may also be interested in...
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.